**Chronic Obstructive Pulmonary Disease: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis**

**Description:**
While the chronic obstructive pulmonary disease (COPD) market will see downward pressure from the arrival of generic versions of key marketed brands, new products will drive positive growth during 2015-24.

This report addresses the following questions:

- How will the emergence of numerous long-acting beta 2 agonist/long-acting muscarinic antagonist (LABA/LAMA) combinations and triple combinations impact the gold standard Spiriva?
- Which are the preferred LABA/LAMA combinations among pulmonologists?
- How will triple combination therapies fit into the COPD treatment algorithm?
- What role will administration frequency play in choice of therapy?
- How will the availability of generics affect sales of key marketed drugs?
- What role will biologics play in COPD?

**Contents:**

**FORECAST: CHRONIC OBSTRUCTIVE PULMONARY DISEASE**

- Executive Summary
- Market Overview and Trends
- Market Definition and Methodology
- Advair (fluticasone/salmeterol)
- Anoro Ellipta (umeclidinium/vilanterol)
- Arcapta (indacaterol)
- Breo (fluticasone furoate/vilanterol)
- CHF 5 (beclometasone/formoterol/glycopyrrolate)
- Daliresp (rofumilast)
- Duaklir Genuair (aclidinium/formoterol)
- Dulera (mometasone/formoterol)
- FF/UMEC/VI (fluticasone/umeclidinium/vilanterol)
- Incruse (umeclidinium)
- Nucala (mepolizumab)
- PT
- (formoterol/glycopyrrolate)
- PT
- (budesonide/glycopyrronium/Formoterol)
- Seebri Breezhaler (glycopyrrolate)
- Spiriva (tiotropium)
- Striolo Respimat (olodaterol/tiotropium)
- Striverdi Respimat (olodaterol)
- Symbicort (budesonide/formoterol)
- Tudorza Pressair (aclidinium)
- Ultibro (indacaterol/glycopyrronium bromide)
- Primary Research Methodology

**TREATMENT: CHRONIC OBSTRUCTIVE PULMONARY DISEASE**

- Executive Summary
- Primary Research Methodology
- Disease Definition and Diagnosis
- Patient Segmentation
- Country Treatment Trees
- Current Treatment Options
- Prescribing Trends
EPIDEMIOLOGY: COPD IN THE US, JAPAN, AND 5EU

- Executive Summary
- Disease Background
- Sources and Methodology
- Forecast
- Epidemiologist Insight
- Strengths and Limitations
- Bibliography

EPIDEMIOLOGY: COPD IN BRAZIL

- Executive Summary
- Disease Background
- Sources and Methodology
- Forecast
- Epidemiologist Insight
- Strengths and Limitations
- Bibliography

MARKETED DRUGS: CHRONIC OBSTRUCTIVE PULMONARY DISEASE

- Executive Summary
- Product Overview
- Other Marketed Drugs for COPD
- Appendix
- Product profile: Advair
- Product profile: Anoro
- Product profile: Arcapta Neohaler
- Product profile: Breo
- Product profile: Daliresp
- Product profile: Duaklir Genuair
- Product profile: Incruse
- Product profile: Seebri Breezhaler
- Product profile: Spiriva
- Product profile: Stiolto Respimat
- Product profile: Striverdi Respimat
- Product profile: Symbicort
- Product profile: Tudorza Pressair
- Product profile: Ultibro

PIPELINE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE

- Executive Summary
- Clinical Pipeline Overview
- Recently Discontinued Drugs
- Appendix
- Product profile (late stage): CHF 59
- Product profile (late stage): FF/UMEC/VI
- Product profile (late stage): Nucala
- Product profile (late stage): PT0
- Product profile (late stage): PT0
- Product profile (late stage): benralizumab

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3797418/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Chronic Obstructive Pulmonary Disease: Epidemiology and Patient-Based MarketForecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis
Web Address: http://www.researchandmarkets.com/reports/3797418/
Office Code: SCH3LQGW

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) -</td>
<td>USD 5000</td>
</tr>
<tr>
<td>Single User:</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td>USD 17500</td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td></td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [Mr] [Mrs] [Dr] [Miss] [Ms] [Prof]
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer:
Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: __________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World